research Alopecia Areata–Specific Patient-Reported Outcome Measures
High-quality validation studies are needed to improve alopecia areata patient-reported outcome measures.
Search
for
Sort by
Research
300-330 / 1000+ resultsresearch Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Innovative Approaches to the Assessment of Alopecia Areata: Incorporating the SALT Index Through Transparent Devices
research Answers for Self-Assessment examination of the American Academy of Dermatology
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Evaluation of serum Level of Human Beta Defensin 1 patients With Alopecia Areata
Human Beta Defensin 1 levels do not predict the risk or severity of Alopecia Areata.
research Evaluation of some biochemical markers in alopecia areata
People with alopecia areata have different blood markers that suggest inflammation and immune system issues compared to healthy individuals.
research Final Phase in the Validation of the Cross-Cultural Adaptation of the Hair-Specific Skindex-29 Questionnaire Into Spanish: Sensitivity to Change and Correlation With the 12-Item Short-Form Health Survey
The Spanish Hair-Specific Skindex-29 questionnaire effectively measures the quality of life impact of hair loss in Spanish-speaking women.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research Serum levels of interleukin-1 (IL-1α, IL-1β) in patients with alopecia areata
IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.
research Oral Baricitinib Restores Hair Loss in Alopecia Areata
Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
research Editorial: Software survey section
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research A Critical Evaluation of Evaluations for Long-form Question Answering
Current methods can't accurately predict which long-form answers people prefer; evaluations should consider different answer qualities separately.
research An Evaluation System to Enhance Patient Selection for Alopecia-Reducing Surgery
The evaluation system improved patient selection for hair loss surgery, leading to better results and satisfaction.
research The quality of E uropean dermatological guidelines: critical appraisal of the quality of EDF guidelines using the AGREE II instrument
European dermatological guidelines vary in quality, with some highly rated, but improvements are needed in applicability and consistency.
research Efficacy of Oral Apremilast in The Treatment of Alopecia Areata, at The Tertiary Care Hospital, Karachi
Oral Apremilast effectively treats alopecia areata in most patients.
research Long‐term outcomes of intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata: A single‐center retrospective analysis of 106 cases and usefulness evaluation of a scoring system originally designed for half‐year efficacy prediction for extended periods
Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
Baricitinib is effective and safe for treating severe alopecia areata.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Free Androgen Index (FAI): Marker of Premature Androgenetic Alopecia in Men
The Free Androgen Index (FAI) is the best indicator of early hair loss in men before age 30.
research Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata
Certain HLA class II alleles increase or decrease the risk of alopecia areata.
research Enhanced stratification of male pattern hair loss using AI through novel loss region ratio analysis
AI improves accuracy and consistency in diagnosing male pattern hair loss.
research Using disease symptomatology to guide treatment in patients with central centrifugal cicatricial alopecia: introduction of C-CAT scoring tool
The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.
research Frontal Fibrosing Alopecia Quality of Life Index: A Validated Disease-Specific Questionnaire Involving Women
The FFA-QLI is a reliable tool for assessing quality of life in women with severe Frontal Fibrosing Alopecia.